Retrospective analysis of clinical outcomes and risk factors in hematopoietic cell transplantation for relapsed or refractory mantle cell lymphoma in the post-ibrutinib era
Real-world data on transplant outcomes helps doctors make better decisions for lymphoma patients whose cancer returns after newer drug treatments.
This Japanese registry study analyzed HCT outcomes in relapsed/refractory mantle cell lymphoma patients in the post-ibrutinib era, providing real-world data on transplant decision-making. The findings inform clinical practice for MCL patients who progress after BTK inhibitor therapy.
What the study was
- Study design
- Retrospective cohort (registry-based)
- Population
- Patients with relapsed/refractory mantle cell lymphoma post-ibrutinib
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Scientific Reports
Why it surfaced
Clinically relevant real-world data for R/R MCL management post-BTK inhibitors. Retrospective registry design limits novelty.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.